Disease-Modifying Therapeutics for Huntington’s Disease: State of the Art
International Journal of Molecular Sciences · 17.11.2026 · 27 (22) · 10301
DOI: 10.3390/ijms272210301 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.11.2026. Verfasst von Gloria Ros und 6 weiteren Autor:innen. Die Arbeit nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: project “National Center for Gene Therapy and Drugs based on RNA Technology”, NextGenerationEU.
Abstract (Originalsprache)
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion in HTT. Despite its well-defined genetic cause, developing safe and effective disease-modifying therapies has remained challenging. By September 2026, the therapeutic landscape included regulatory submissions for the adeno-associated virus serotype 5 (AAV5)-delivered RNA interference therapy ifezuntirgene inilparvovec (AMT-130) and the discontinuation of tominersen after the GENERATION HD2 trial, in which target engagement and biomarker responses were achieved without clinical benefit. These contrasting developments highlight both the progress achieved and the challenges of translating molecular interventions into clinical benefit. Here, we review five complementary therapeutic strategies grounded in current understanding of HD pathogenesis: editing the HTT sequence or modifying its epigenetic regulation; suppressing somatic CAG expansion by modulating DNA repair; lowering huntingtin expression with antisense oligonucleotides, AAV-delivered RNA interference and oral splicing modulators; modifying mutant huntingtin aggregation and proteostasis; and targeting downstream pathological processes. Together, these advances support combination approaches targeting multiple pathogenic mechanisms, although their efficacy and safety remain to be established. More than three decades after the identification of the causative mutation, a deeper understanding of HD biology and expanding therapeutic approaches provide grounds for cautious optimism about meaningful improvements for people with HD.
Förderung
- project “National Center for Gene Therapy and Drugs based on RNA Technology”
- NextGenerationEU
Zitieren
APA
Ros, G., Bon, C., Smělá, D., Espinoza, S., Sanges, R., Gustincich, S., & Persichetti, F. (2026). Disease-Modifying Therapeutics for Huntington’s Disease: State of the Art. International Journal of Molecular Sciences, 27(22), 10301. https://doi.org/10.3390/ijms272210301
Vancouver
Ros G, Bon C, Smělá D, Espinoza S, Sanges R, Gustincich S, et al. Disease-Modifying Therapeutics for Huntington’s Disease: State of the Art. International Journal of Molecular Sciences. 2026;27(22):10301. doi:10.3390/ijms272210301
BibTeX
@article{Ros2026,
author = {Ros, Gloria and Bon, Carlotta and Smělá, Denisa and Espinoza, Stefano and Sanges, Remo and Gustincich, Stefano and Persichetti, Francesca},
title = {Disease-Modifying Therapeutics for Huntington’s Disease: State of the Art},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {22},
pages = {10301},
doi = {10.3390/ijms272210301}
}
EUVIMED